Label: EZETIMIBE tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 27, 2023

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    EZETIMIBE Tablets. These highlights do not include all the information needed to use EZETIMIBE Tablets safely and effectively. See full prescribing information for EZETIMIBE Tablets.
    EZETIMIBE Tablets, for oral use
    Initial U.S. Approval: 2002

    RECENT MAJOR CHANGES

    Indications and Usage (1)07/2023
    Dosage and Administration (2)07/2023
    Contraindications (4)07/2023
    Warnings and Precautions ( 5.1, 5.2, 5.3) 07/2023

    INDICATIONS AND USAGE

    Ezetimibe tablets are indicated (1):

    • In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

    • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.

    In combination with fenofibrate as an adjunct to diet to reduce elevated LDL C in adults with mixed hyperlipidemia.

    • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).

    • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.

    When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use (1).

    DOSAGE AND ADMINISTRATION

    • One 10 mg tablet once daily, with or without food (2)
    • Administer ezetimibe tablets either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. (2)
    • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets. (2)

    DOSAGE FORMS AND STRENGTHS

    • Tablets: 10 mg (3)

    CONTRAINDICATIONS

    • Hypersensitivity to ezetimibe or any excipient of ezetimibe tablets. (4)

    • When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications. (4)

    WARNINGS AND PRECAUTIONS

    • Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies: Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions. (5.1)

    • Liver Enzyme Abnormalities and Monitoring: Increases in serum transaminases have been reported with use of ezetimibe tablets. Perform liver enzyme testing as clinically indicated and consider withdrawal of ezetimibe tablets if increases in ALT or AST ≥3 X ULN persist. (5.2)

    • Skeletal Muscle Effects (e.g., Myopathy and Rhabdomyolysis): Ezetimibe tablets may cause myopathy and rhabdomyolysis. In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates. If myopathy is suspected, discontinue ezetimibe tablets and other concomitant medications, as appropriate. (5.3)

    ADVERSE REACTIONS

    • Common adverse reactions in clinical trials:
    • Ezetimibe tablets administered alone (incidence ≥2% and greater than placebo): upper

    respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and
    influenza (6.1)

    • Ezetimibe tablets coadministered with a statin (incidence ≥2% and greater than statin

    alone): nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea,
    back pain, influenza, pain in extremity, and fatigue (6.1)


    To report SUSPECTED ADVERSE REACTIONS, contact Ohm Laboratories Inc. at 1-800- 406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.[see Warnings and Precautions (5.2)][see Warnings and Precautions (5.3)]

    DRUG INTERACTIONS

    • Cyclosporine: Combination increases exposure of ezetimibe tablets and cyclosporine. Cyclosporine concentrations should be monitored in patients taking ezetimibe tablets concomitantly. (7)
    • Fibrates: Co-administration of ezetimibe tablets with fibrates other than fenofibrate is not recommended until use in patients is adequately studied. If cholelithiasis is suspected in a patient receiving ezetimibe tablets and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered. (7)
    • Bile Acid Sequestrants: Cholestyramine combination decreases exposure of ezetimibe tablets. (7)

    See 17 for PATIENT COUNSELING INFORMATIONand FDA-approved patient labeling.

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 12/2023

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Ezetimibe tablets are indicated:

    • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

    • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.

    • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.

    In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).

    • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.

    When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.

  • 2 DOSAGE AND ADMINISTRATION

    • The recommended dose of ezetimibe tablet is 10 mg orally once daily, administered with or without food.
    • If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.
    • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets.
    • In patients taking a bile acid sequestrant, administer ezetimibe tablets at least 2 hours before or 4 hours after the bile acid sequestrant [ see Drug Interactions (7)].
  • 3 DOSAGE FORMS AND STRENGTHS

    10 mg tablets are white to off-white, capsule-shaped uncoated tablets with " E 10" debossed on one side and plain on other side.

  • 4 CONTRAINDICATIONS

    Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [ see Adverse Reactions (6.2)].

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDLC lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies

    If ezetimibe tablets are administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4)].

    5.2 Liver Enzymes

    Increases in serum transaminases have been reported with use of ezetimibe tablets [see Adverse Reactions (6.1)]. In controlled clinical combination studies of ezetimibe tablets initiated concurrently with a statin, the incidence of consecutive elevations (≥3 X ULN) in hepatic transaminase levels was 1.3% for patients treated with ezetimibe tablets administered with statins and 0.4% for patients treated with statins alone. Perform liver enzyme testing as clinically indicated and consider withdrawal of ezetimibe tablets if increases in ALT or AST ≥3 X ULN persist.

    5.3 Myopathy/Rhabdomyolysis

    Ezetimibe tablets may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis [see Adverse Reactions (6.1)]. In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates. If myopathy is suspected, discontinue ezetimibe tablets and other concomitant medications, as appropriate.

  • 6 ADVERSE REACTIONS


    The following serious adverse reactions are discussed in greater detail in other sections of the label:

    • Liver enzyme abnormalities [see Warnings and Precautions (5.2)]

    • Rhabdomyolysis and myopathy [see Warnings and Precautions (5.3)]

    6.1 Clinical Trials Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a

    drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical

    practice.

    Monotherapy

    In 10 double-blind, placebo-controlled clinical trials, 2,396 patients with primary hyperlipidemia (age range 9 to 86 years; 50% female, 90% White, 5% Black or African American, 2% Asian, 3% other races; 3% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ezetimibe tablets 10 mg daily for a median treatment duration of 12 weeks (range 0 to 39 weeks).

    Adverse reactions reported in ≥ 2% of patients treated with ezetimibe tablets and at an incidence greater than placebo in placebo-controlled studies of ezetimibe tablets are shown in Table 1.

    TABLE 1: Adverse Reactions Occurring in ≥ 2% and Greater than Placebo in ezetimibe tablets -treated Patients

    Adverse ReactionsPlacebo (%) n=1,159

    Ezetimibe tablets 10mg (%)

    n=2,396

    Upper respiratory tract infection2.54.3
    Diarrhea3.74.1
    Arthralgia2.23.0
    Sinusitis2.22.8
    Pain in extremity2.52.7
    Fatigue1.52.4
    1.52.0

    Combination with a Statin

    In 28 double-blind, controlled (placebo or active-controlled) clinical trials, 11,308 patients with primary hyperlipidemia (age range 10 to 93 years, 48% female, 85% White, 7% Black or African

    American, 3% Asian, 5% other races; 4% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ezetimibe tablets 10 mg/day concurrently with or added to on-going statin therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).

    The incidence of consecutive increased transaminases (≥ 3 times ULN) was higher in patients receiving ezetimibe tablets administered with statins (1.3%) than in patients treated with statins alone (0.4%).

    Adverse reactions reported in ≥2% of patients treated with ezetimibe tablets + statin and at an incidence greater than statin are shown in Table 2.

    TABLE 2: Adverse Reactions Occurring ≥2% in ezetimibe tablets -treated Patients Co-administered with a Statin and at an Incidence Greater than Statin

    Adverse Reaction

    All Statins*

    (%)

    n = 9,361

    All Statins*

    (%)

    n = 9,361

    Ezetimibe Tablets + All Statins*

    (%)

    n = 11,308

    Nasopharyngitis3.33.7
    Myalgia2.73.2
    Upper respiratory tract infection2.82.9
    Arthralgia2.42.6
    Diarrhea2.22.5
    Back pain2.32.4
    Influenza2.12.2
    Pain in extremity1.92.1
    Fatigue1.62.0

    *All Statins = all doses of all statins

    Combination with Fenofibrate

    This clinical trial involving 625 patients with mixed dyslipidemia (age range 20 to 76 years; 44% female, 79% White, 1% Black or African American, 20% other races; 11% identified as Hispanic or Latino ethnicity) treated for up to 12 weeks and 576 patients treated for up to an additional 48 weeks evaluated co-administration of ezetimibe tablets and fenofibrate. Incidence rates for clinically important elevations (≥3 X ULN, consecutive) in hepatic transaminase levels were 4.5% and 2.7% for fenofibrate monotherapy (n=188) and ezetimibe tablets co-administered with fenofibrate (n=183), respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6% and 1.7% for fenofibrate monotherapy and ezetimibe tablets co-administered with fenofibrate, respectively [see Drug Interactions (7)].

    6.2 Post-Marketing Experience

    Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    The following additional adverse reactions have been identified during post-approval use of ezetimibe tablets:

    Blood Disorders:thrombocytopenia

    Gastrointestinal Disorders:abdominal pain; pancreatitis; nausea

    Hepatobiliary Disorders:elevations in liver transaminases; hepatitis; cholelithiasis; cholecystitis

    Immune System Disorders:Hypersensitivity reactions including: anaphylaxis, angioedema, rash, and urticaria

    Musculoskeletal Disorders:elevated creatine phosphokinase; myopathy/rhabdomyolysis

    Nervous System Disorders:dizziness; paresthesia; depression; headache

    Skin and Subcutaneous Tissue Disorders:erythema multiforme

  • 7 DRUG INTERACTIONS

    Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with ezetimibe and instructions for preventing or managing them.

    Table 3 Clinically Important Drug Interactions with Ezetimibe Tablets
    Cyclosporine
    Clinical ImpactConcomitant use of ezetimibe tablets and cyclosporine increases ezetimibe and cyclosporine concentrations. The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency [see Clinical Pharmacology ( 12.3)] .
    InterventionMonitor cyclosporine concentrations in patients receiving ezetimibe tablets and cyclosporine. In patients treated with cyclosporine, weigh the potential effects of the increased exposure to ezetimibe from concomitant use against the benefits of alterations in lipid levels provided by ezetimibe tablets.
    Fibrates
    Clinical ImpactBoth fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. Co-administration of ezetimibe tablets with fibrates other than fenofibrate is not recommended [see Adverse Reactions ( 6.1)] .
    InterventionIf cholelithiasis is suspected in a patient receiving ezetimibe tablets and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered.
    Bile Acid Sequestrants
    Clinical ImpactConcomitant cholestyramine administration decreased the mean exposure of total ezetimibe. This may result in a reduction of efficacy [see Clinical Pharmacology ( 12.3)] .
    InterventionIn patients taking a bile acid sequestrant, administer ezetimibe tablets at least 2 hours before or 4 hours after the bile acid sequestrant [see Dosage and Administration ( 2)] .
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are insufficient data on ezetimibe use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits orally administered ezetimibe during the period of organogenesis at doses that resulted in up to 10 and 150 times, respectively, the human exposure at the MRHD, based on AUC (see Data). Ezetimibe tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When ezetimibe tablets are administered with a statin, refer to the Prescribing Information for the statin.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Data

    Animal Data

    In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats (gestation days 6-15) and rabbits (gestation days 7-19), there was no evidence of maternal toxicity or embryolethal effects at the doses tested (250, 500, 1,000 mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1,000 mg/kg/day (~10 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1,000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe). The animal-to-human exposure multiple for total ezetimibe at the no-observed effect level was 6 times for rat and 134 times for rabbit. Fetal exposure to ezetimibe (conjugated and unconjugated) was confirmed in subsequent placental transfer studies conducted using a maternal dose of 1,000 mg/kg/day. The fetal maternal plasma exposure ratio (total ezetimibe) was 1.5 for rats on gestation day 20 and 0.03 for rabbits on gestation day 22.

    The effect of ezetimibe on prenatal and postnatal development and maternal function was evaluated in pregnant rats at doses of 100, 300 or 1,000 mg/kg/day from gestation day 6 through lactation day 21. No maternal toxicity or adverse developmental outcomes were observed up to and including the highest dose tested (17 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe).

    Multiple-dose studies of ezetimibe given in combination with statins in rats and rabbits during organogenesis resulted in higher ezetimibe and statin exposures. Reproductive findings occurred at lower doses in combination therapy compared to monotherapy.

    8.2 Lactation

    Risk Summary

    There is no information about the presence of ezetimibe in human milk. Ezetimibe is present in rat milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. There is no information about the effects of ezetimibe on the breastfed infant or the effects of ezetimibe on milk production. Ezetimibe tablets should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.

    Data

    Ezetimibe was present in the milk of lactating rats. The pup to maternal plasma ratio for total ezetimibe was 0.5 on lactation day 12.

    8.4 Pediatric Use

    The safety and effectiveness of ezetimibe tablets in combination with a statin as an adjunct to diet to reduce LDL-C have been established in pediatric patients 10 years of age and older with HeFH. Use of ezetimibe tablets for this indication is based on a double-blind, placebo-controlled clinical trial in 248 pediatric patients (142 males and 106 postmenarchal females) 10 years of age and older with HeFH [see Clinical Studies (14)]. In this limited controlled trial, there was no significant effect on growth or sexual maturation in the adolescent males or females, or on menstrual cycle length in females.

    The safety and effectiveness of ezetimibe tablets in combination with a statin, and other LDL-C lowering therapies, to reduce LDL-C have been established in pediatric patients 10 years of age and older with HoFH. Use of ezetimibe tablets for this indication is based on a 12-week double-blind, placebo-controlled clinical trial followed by an uncontrolled extension period in 7 pediatric patients 11 years of age and older with HoFH [see Clinical Studies (14)].

    The safety and effectiveness of ezetimibe tablets as an adjunct to diet for the reduction of elevated sitosterol and campesterol levels have been established in adults and pediatric patients 9 years of age and older with homozygous familial sitosterolemia. Use of ezetimibe tablets for this indication is based on an 8-week double-blind, placebo-controlled clinical trial in 4 patients 9 years of age and older with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) [see Clinical Studies (14)].

    The safety and effectiveness of ezetimibe tablets have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, in pediatric patients younger than 9 years of age with homozygous familial sitosterolemia, or in pediatric patients with other types of hyperlipidemia.

    8.5 Geriatric Use

    Of the 2,396 patients who received ezetimibe tablets in clinical trials, 669 (28%) were 65 years of age and older, and 111 (5%) were 75 years of age and older. Of the 11,308 patients who received ezetimibe tablets in combination with a statin in clinical trials, 3587 (32%) were 65 years of age and older, and 924 (8%) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety or effectiveness of ezetimibe tablets have been observed between patients 65 years of age and older and younger patients. No clinically meaningful differences in the pharmacokinetics of ezetimibe were observed in geriatric patients compared to younger adult patients [see Clinical Pharmacology (12.3)].

    8.6 Renal Impairment

    No dosage adjustment of ezetimibe tablets is necessary in patients with renal impairment.

    8.7 Hepatic Impairment

    Ezetimibe tablets are not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to the unknown effects of the increased exposure to ezetimibe [ see Clinical Pharmacology (12.3)].

  • 10 OVERDOSAGE

    In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

  • 11 DESCRIPTION

    Ezetimibe is a dietary cholesterol absorption inhibitor. The chemical name of ezetimibe is 1-(4- fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.42 and its structural formula is:

    Structure

    Ezetimibe is a white to off white, crystalline powder that is freely soluble in methanol, and acetone, soluble in ethanol, and practically insoluble in water. Ezetimibe has a melting point of about 165.13°C and is stable at ambient temperature. Ezetimibe is available as a tablet for oral administration containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone, pregelatinized starch (maize) and sodium lauryl sulfate.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.

    The molecular target of ezetimibe has been shown to be the sterol transporter,

    Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and

    phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.

    12.2 Pharmacodynamics

    Ezetimibe tablets reduces total cholesterol (total-C), LDL-C, apolipoprotein (Apo) B, and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with hyperlipidemia.

    In a 2-week clinical trial in 18 hypercholesterolemic patients, ezetimibe tablets inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe tablets had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E (in a trial of 113 patients) and did not impair adrenocortical steroid hormone production (in a trial of 118 patients).

    12.3 Pharmacokinetics

    Absorption

    After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). After a single 10 mg dose of ezetimibe tablets to fasted adults, mean ezetimibe peak plasma concentrations (C max) of 3.4 to 5.5 ng/mL were attained within 4 to 12 hours (T max). Ezetimibe-glucuronide mean C maxvalues of 45 to 71 ng/mL were achieved between 1 and 2 hours (T max). There was no substantial deviation from dose proportionality between 5 and 20 mg. The absolute bioavailability of ezetimibe cannot be determined, as the compound is virtually insoluble in aqueous media suitable for injection.

    Effect of Food

    Concomitant food administration (high-fat or non-fat meals) had no effect on the extent of absorption of ezetimibe when administered as ezetimibe 10 mg tablets. The C maxvalue of ezetimibe was increased by 38% with consumption of high-fat meals.

    Distribution

    Ezetimibe and ezetimibe-glucuronide are highly bound (> 90%) to human plasma proteins.

    Elimination

    Metabolism

    Ezetimibe is primarily metabolized in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary and renal excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively.

    Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide. Plasma concentration-time profiles exhibit multiple peaks, suggesting enterohepatic recycling

    Excretion

    Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe (ezetimibe + ezetimibe-glucuronide) accounted for approximately 93% of the total radioactivity in plasma. After 48 hours, there were no detectable levels of radioactivity in the plasma.

    Approximately 78% and 11% of the administered radioactivity were recovered in the feces and urine, respectively, over a 10-day collection period. Ezetimibe was the major component in feces and accounted for 69% of the administered dose, while ezetimibe-glucuronide was the major component in urine and accounted for 9% of the administered dose.

    Specific Populations

    Geriatric Patients: In a multiple-dose trial with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were about 2-fold higher in older (≥ 65 years) healthy subjects compared to younger subjects. However, the difference in plasma concentrations is not clinically meaningful.

    Gender: In a multiple-dose trial with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were slightly higher (< 20%) in females than in males.

    Race: Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and White subjects. Studies in Asian subjects indicated that the pharmacokinetics of ezetimibe were similar to those seen in White subjects.

    Renal Impairment:After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl ≤30 mL/min/1.73 m 2), the mean AUC values for total ezetimibe, ezetimibe-glucuronide, and ezetimibe were increased approximately 1.5-fold, compared to healthy subjects (n=9).

    Hepatic Impairment:After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 to 6), compared to healthy subjects. The mean AUC values for total ezetimibe and ezetimibe were increased approximately 3-to 4-fold and 5-to 6-fold, respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe hepatic impairment (Child-Pugh score 10 to 15). In a 14-day, multiple-dose trial (10 mg daily) in patients with moderate hepatic impairment, the mean AUC values for total ezetimibe and ezetimibe were increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects [see Use in Specific Populations (8.7)].

    Drug Interactions

    Ezetimibe tablets had no significant effect on a series of probe drugs (caffeine, dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a “cocktail” trial of twelve healthy adult males. This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes.

    TABLE 4: Effect of Co-Administered Drugs on Total Ezetimibe

    Coadministered Drug and Dosing RegimenTotal Ezetimibe*
    Change in AUCChange in C max
    Cyclosporine-stable dose required (75 mg to 150 mg BID )†, ‡↑240%↑290%
    Fenofibrate, 200 mg QD, 14 days ‡↑48%↑64%
    Gemfibrozil, 600 mg BID, 7 days ‡↑64%↑91%
    Cholestyramine, 4 g BID, 14 days ‡↓55%↓4%
    Aluminum & magnesium hydroxide combination antacid, single dose §↓4%↓30%
    Cimetidine, 400 mg BID, 7 days↑6%↑22%
    Glipizide, 10 mg, single dose↑4%↓8%
    Statins
    Lovastatin 20 mg QD, 7 days↑9%↑3%
    Pravastatin 20 mg QD, 14 days↑7%↑23%
    Atorvastatin 10 mg QD, 14 days↓2%↑12%
    Rosuvastatin 10 mg QD, 14 days↑13%↑18%
    Fluvastatin 20 mg QD, 14 days↓19%↑7%

    * Based on 10 mg dose of ezetimibe

    † Post-renal transplant patients with mild impaired or normal renal function. In a different trial, a renal transplant patient with severe renal insufficiency (creatinine clearance of 13.2 mL/min/1.73 m2) who was receiving multiple medications, including cyclosporine, demonstrated a 12-fold greater exposure to total ezetimibe compared to healthy subjects.

    ‡ See Drug Interactions (7).

    § Supralox, 20 mL

    TABLE 5: Effect of Ezetimibe Co-Administration on Systemic Exposure to Other Drugs

    Coadministered Drug and its Dosage Regimen

    Ezetimibe Dosage RegimenChange in AUC of Coadministered DrugChange in C max of
    Coadministered Drug
    Warfarin, 25 mg single dose on day 710 mg QD, 11 days↓2% (R-warfarin)
    ↓4% (S-warfarin)
    ↑3% (R-warfarin)
    ↑1% (S-warfarin)
    Digoxin, 0.5 mg single dose10 mg QD, 8 days↑2%↓7%
    Gemfibrozil, 600 mg BID, 7 days*10 mg QD, 7 days↓1%↓11%
    Ethinyl estradiol & Levonorgestrel, QD, 21 days10 mg QD, days 8 to 14 of 21d oral contraceptive cycleEthinyl estradiol 0% Levonorgestrel
    0%
    Ethinyl estradiol
    ↓9%
    Levonorgestrel
    ↓5%
    Glipizide, 10 mg on days 1 and 910 mg QD, days 2 to 9↓3%↓5%
    Fenofibrate, 200 mg QD, 14 days*10 mg QD, 14 days↑11%↑7%
    Cyclosporine, 100 mg single dose day 7*20 mg QD, 8 days↑15%↑10%
    Statins
    Lovastatin 20 mg QD, 7 days10 mg QD, 7 days↑19%↑3%
    Pravastatin 20 mg QD, 14 days10 mg QD, 14 days↓20%↓24%
    Atorvastatin 10 mg QD, 14 days10 mg QD, 14 days↓4%↑7%
    Rosuvastatin 10 mg QD, 14 days10 mg QD, 14 days↑19%↑17%
    Fluvastatin 20 mg QD, 14 days10 mg QD, 14 days↓39%↓27%

    * See Drug Interactions (7).

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (> 150 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice.

    No evidence of mutagenicity was observed in vitroin a microbial mutagenicity (Ames) test with Salmonella typhimuriumand Escherichia coliwith or without metabolic activation. No evidence of clastogenicity was observed in vitroin a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation. In addition, there was no evidence of genotoxicity in the in vivomouse micronucleus test.

    In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC 0-24hrfor total ezetimibe).

  • 14 CLINICAL STUDIES

    Primary Hyperlipidemia in Adults

    Ezetimibe tablets reduces total-C, LDL-C, Apo B, and non-HDL-C in patients with hyperlipidemia. Maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.

    Monotherapy

    In two multicenter, double-blind, placebo-controlled, 12-week trials in 1719 patients (age range 18 to 86 years, 52% females; 91% White, 5% Black or African American, 1% Asian, 3% other races mostly identified as Hispanic or Latino ethnicity) with primary hyperlipidemia, ezetimibe tablets significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to placebo (see Table 7). Reduction in LDL-C was consistent across age, sex, and baseline LDL-C.

    TABLE 7: Response to Ezetimibe Tablets in Patients with Primary Hyperlipidemia (Mean % Change from Untreated Baseline†)

    Treatment GroupNTotal-CLDL-CApo BNon-HDL-C
    Trial 1 ‡Placebo205+1+1-1+1
    Ezetimibe622-12-18-15-16
    Trial 2 ‡Placebo226+1+1-1+2
    Ezetimibe666-12-18-16-16
    Pooled Data ‡(Trials 1 & 2)Placebo4310+1-2+1
    Ezetimibe1288-13-18-16-16

    † Baseline - on no lipid-lowering drug

    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    On-going Statin+Placebo §390-2-4-3-3
    On-going Statin+Ezetimibe §379-17-25-19-23
    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    Placebo60+4+4+3+4
    Ezetimibe tablets65-14-20-15-18
    Atorvastatin 10 mg60-26-37-28-34
    Ezetimibe tablets+Atorvastatin 10 mg65-38-53-43-49
    Atorvastatin 20 mg60-30-42-34-39
    Ezetimibe tablets+Atorvastatin 20 mg62-39-54-44-50
    Atorvastatin 40 mg66-32-45-37-41
    Ezetimibe tablets+Atorvastatin 40 mg65-42-56-45-52
    Atorvastatin 80 mg62-40-54-46-51
    Ezetimibe tablets+Atorvastatin 80 mg63-46-61-50-58
    Pooled data (All Atorvastatin Doses) ‡248-32-44-36-41
    Pooled data (All Ezetimibe tablets+Atorvastatin Doses) ‡255-41-56-45-52
    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    Placebo70-1-10-1
    Ezetimibe Tablets61-13-19-14-17
    Simvastatin 10 mg70-18-27-21-25
    Ezetimibe Tablets+Simvastatin 10 mg67-32-46-35-42
    Simvastatin 20 mg61-26-36-29-33
    Ezetimibe Tablets+Simvastatin 20 mg69-33-46-36-42
    Simvastatin 40 mg65-27-38-32-35
    Ezetimibe Tablets+Simvastatin 40 mg73-40-56-45-51
    Simvastatin 80 mg67-32-45-37-41
    Ezetimibe Tablets+Simvastatin 80 mg65-41-58-47-53
    Pooled data (All Simvastatin Doses) ‡263-26-36-30-34
    Pooled data (All Ezetimibe Tablets+Simvastatin Doses) ‡274-37-51-41-47
    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    Placebo650-1-20
    Ezetimibe tablets64-13-20-15-17
    Pravastatin 10 mg66-15-21-16-20
    Ezetimibe tablets+Pravastatin 10 mg71-24-34-27-32
    Pravastatin 20 mg69-15-23-18-20
    Ezetimibe tablets+Pravastatin 20 mg66-27-40-31-36
    Pravastatin 40 mg70-22-31-26-28
    Ezetimibe tablets+Pravastatin 40 mg67-30-42-32-39
    Pooled data (All Pravastatin Doses )‡205-17-25-20-23
    Pooled data (All Ezetimibe tablets+Pravastatin Doses) ‡204-27-39-30-36
    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    Placebo64+10+1+1
    Ezetimibe tablets72-13-19-14-16
    Lovastatin 10 mg73-15-20-17-19
    Ezetimibe tablets+Lovastatin 10 mg65-24-34-27-31
    Lovastatin 20 mg74-19-26-21-24
    Ezetimibe tablets+Lovastatin 20 mg62-29-41-34-39
    Lovastatin 40 mg73-21-30-25-27
    Ezetimibe tablets+Lovastatin 40 mg65-33-46-38-43
    Pooled data (All Lovastatin Doses) ‡220-18-25-21-23
    Pooled data (All Ezetimibe tablets+Lovastatin Doses) ‡192-29-40-33-38
    Treatment (Daily Dose)NTotal-CLDL-CApo BNon-HDL-C
    Placebo6300-10
    Ezetimibe Tablets185-12-13-11-15
    Fenofibrate 160 mg188-11-6-15-16
    Ezetimibe Tablets+Fenofibrate 160 mg183-22-20-26-30
    Table 14 Mean Percent Difference at Week 6 Between the Pooled Ezetimibe Tablets Coadministered with Simvastatin Group and the Pooled Simvastatin Monotherapy Group in Adolescent Patients with HeFH
    Total-CLDL-CApo BNon-HDL-C
    Mean percent difference between treatment groups-12%-15%-12%-14%
    95% Confidence Interval(-15%, -9%)(-18%, -12%)(-15%, -9%)(-17%, -11%)

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Ezetimibe tablets, USP, 10 mg, are white to off-white, capsule-shaped uncoated tablets with “ E 10” debossed on one side and plain on other side. They are supplied as follows:

    NDC60429-982-30 Bottles of 30

    NDC60429-982-90 Bottles of 90

    NDC60429-982-05 Bottles of 500

    Storage

    Store at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature]. Protect from moisture.

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).

    Inform patients that ezetimibe tablets may cause liver enzyme elevations [see Warnings and Precautions (5.2)].

    Muscle Pain

    Advise patients that ezetimibe tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.3), andDrug Interactions (7)].

    Pregnancy

    Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if ezetimibe tablets should be discontinued [see Use in Specific Populations (8.1)].

    Breastfeeding

    Advise patients who have a lipid disorder and are breastfeeding to discuss the options with their healthcare provider [see Use in Specific Populations(8.2)].

    Missed Dose

    Instruct patients to take ezetimibe tablets only as prescribed. If a dose is missed, it should be taken as soon as possible. Advise patients not to double their next dose.

    Manufactured by:

    Ohm Laboratories Inc.

    New Brunswick, NJ 08901

    Distributed by:

    Sun Pharmaceuticals Industries, Inc.

    Cranbury, NJ 08512

    August 2023 FDA-06

    5244236

    Marketed by:

    GSMS, Inc.

    Camarillo, CA 93012 USA

  • Patient Information

    EZETIMIBE TABLETS, USP
    (e-zet’-i-mibe)

    Rx only

    Read this information carefully before you start taking ezetimibe tablets, USP and each time you get more ezetimibe tablets, USP. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about ezetimibe tablets, USP, ask your doctor. Only your doctor can determine if ezetimibe tablets, USP are right for you.

    What are ezetimibe tablets, USP?

    Ezetimibe tablets, USP are used with a cholesterol lowering diet:

    • and with other cholesterol medicines called a statin, or alone (when additional cholesterol lowering treatments are not possible), to lower elevated low-density lipoprotein cholesterol (LDL-C) or bad cholesterol in adults with primary hyperlipidemia (too many fats in your blood), including heterozygous familial hypercholesterolemia (HeFH). HeFH is an inherited condition that causes high levels of bad cholesterol.
    • and with a statin to lower LDL-C in adults and children 10 years of age and older with HeFH.
    • and with a medicine called fenofibrate to lower elevated LDL-C in adults with mixed hyperlipidemia.

    to lower elevated sitosterol and campesterol levels in adults and in children 9 years of age and older with homozygous familial sitosterolemia (a rare inherited condition that prevents the body from getting rid of cholesterol from plants).

    Ezetimibe tablets is also used:

    • with a statin and other cholesterol lowering treatments to lower elevated LDL-C levels in adults and patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). HoFH is an inherited condition that causes high levels of bad cholesterol.

    The safety and effectiveness of ezetimibe tablets has not been established in children:

    • younger than 10 years of age with HeFH or HoFH.
    • younger than 9 years of age with homozygous familial sitosterolemia.
    • with other types of hyperlipemia.

    Do not take ezetimibe tablets:

    • if you are allergic to ezetimibe or any of the ingredients in ezetimibe tablets. See the end of this Patient Information leaflet for a complete list of ingredients in ezetimibe tablets. Stop using ezetimibe tablets and get medical help right away if you have symptoms of a serious allergic reaction including:

    o swelling of the face, tongue, or throat

    o difficulty breathing or swallowing

    o fainting or feeling dizzy o very fast heartbeat

    o severe skin rash, hives, and itching

    o flu-like symptoms including fever, sore throat, cough, tiredness, and joint pain

    • with certain statins, fenofibrate, or other LDL-C lowering medicines if your healthcare provider has told you not to take them.

    Before you take ezetimibe tablets, tell your healthcare provider about all your medical conditions, including if you:

    • have liver problems. Ezetimibe tablets may not be right for you.
    • are pregnant or plan to become pregnant. It is not known if ezetimibe tablets will harm your unborn baby. You and your healthcare provider should decide if you will take ezetimibe tablets while you are pregnant.
    • are breastfeeding. It is not known if ezetimibe tablets passes into your breast milk. You and your healthcare provider should decide the best way to feed your baby if you take ezetimibe tablets.

    Tell your healthcare provider about all the medicines you take,including prescription and over-the-­counter medicines, vitamins, and herbal supplements. Talk to your healthcare provider before you start taking any new medicines. Taking ezetimibe tablets with certain other medicines may affect each other causing side effects. Ezetimibe tablets may affect the way other medicines work, and other medicines may affect how ezetimibe tablets works.

    Especially tell your healthcare provider if you take:

    • cyclosporine (a medicine for your immune system)
    • fibrates (medicine for lowering cholesterol)
    • bile acid sequestrants (medicine for lowering LDL-C)

    Ask your healthcare provider or pharmacist for a list of medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    How should I take ezetimibe tablets?

    • Take ezetimibe tablets 1-time each day, with or without food. It may be easier to remember to take your dose if you do it at the same time every day, such as with breakfast, dinner, or at bedtime. If you also take another medicine to reduce your cholesterol, ask your healthcare provider if you can take them at the same time.
    • If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take 2 doses of ezetimibe tablets at the same time.
    • While taking ezetimibe tablets, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.
    • If you take a medicine called a bile acid sequestrant, take ezetimibe tablets at least 2 hours before or 4 hours after you take the bile acid sequestrant.
    • Your healthcare provider may do blood tests to check your LDL-C levels as early as 4 weeks after starting treatment with ezetimibe tablets.
    • In case of an overdose, get medical help or contact a live Poison Center expert right away at 1­-800-222-1222. Advice is also available online at poisonhelp.org.

    What are the possible side effects of ezetimibe tablets?

    Ezetimibe tablets may cause serious side effects including:

    • increased liver enzymes.An increase in liver enzymes can happen in people taking ezetimibe tablets alone or with statins. Your healthcare provider may do blood tests to check your liver before and during treatment. Your healthcare provider may need to change or stop your treatment with ezetimibe tablets because of an increase in liver enzymes.
    • muscle pain, tenderness, and weakness (myopathy). Muscle problems, including muscle breakdown (rhabdomyolysis) can happen. Tell your healthcare provider right away if:
    • you have unexplained muscle pain, tenderness, weakness, feel more tired than usual, or fever.
    • you have muscle problems that do not go away even after your healthcare provider has advised you to stop taking ezetimibe tablets. Your healthcare provider may do further tests to diagnose the cause of your muscle problems.

    Your chances of getting muscle problems are higher if you are also taking statins or fibrates.

    The most common side effects of ezetimibe tablets taken alone include:

    • upper respiratory
    • joint pain
    • pain in arms or
    • flu-like tract infection legs symptoms
    • diarrhea
    • inflammation of the
    • feeling tired sinuses

    The most common side effects of ezetimibe tablets taken with a statin include:

    • runny nose, sore throat
    • joint pain
    • flu-like symptoms
    • muscle aches and pains
    • diarrhea
    • pain in arms or legs
    • upper respiratory tract infection
    • back pain
    • feeling tired

    Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of ezetimibe tablets.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-­FDA-1088.

    How should I store ezetimibe tablets?

    • Store ezetimibe tablets at room temperature between 68ºF to 77ºF (20ºC to 25ºC).
    • Protect from moisture. Keep ezetimibe tablets and all medicines out of the reach of children.

    General information about safe and effective use of ezetimibe tablets.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ezetimibe tablets for a condition for which it was not prescribed. Do not give ezetimibe tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ezetimibe tablets that is written for health professionals.

    What are the ingredients in Ezetimibe tablets?

    Active ingredient:ezetimibe.

    Inactive ingredients:Croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone, pregelatinized starch (maize) and sodium lauryl sulfate.

    Manufactured by:

    Ohm Laboratories Inc.

    New Brunswick, NJ 08901

    Distributed by:

    Sun Pharmaceuticals Industries, Inc.

    Cranbury, NJ 08512

    August 2023 FDA-06

    Marketed by:

    GSMS, Inc.

    Camarillo, CA 93012 USA

  • Package/Label Display Panel

    60429-982-30.jpg

  • INGREDIENTS AND APPEARANCE
    EZETIMIBE 
    ezetimibe tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60429-982(NDC:51660-200)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    EZETIMIBE (UNII: EOR26LQQ24) (EZETIMIBE - UNII:EOR26LQQ24) EZETIMIBE10 mg
    Inactive Ingredients
    Ingredient NameStrength
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)  
    Product Characteristics
    Colorwhite (white to off white) Scoreno score
    ShapeCAPSULESize8mm
    FlavorImprint Code E10
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60429-982-3030 in 1 BOTTLE; Type 0: Not a Combination Product11/06/2017
    2NDC:60429-982-9090 in 1 BOTTLE; Type 0: Not a Combination Product11/06/2017
    3NDC:60429-982-05500 in 1 BOTTLE; Type 0: Not a Combination Product11/06/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20731106/12/2017
    Labeler - Golden State Medical Supply, Inc. (603184490)
    Establishment
    NameAddressID/FEIBusiness Operations
    Golden State Medical Supply, Inc.603184490relabel(60429-982) , repack(60429-982)